吉非替尼治疗31例男性晚期非小细胞肺癌临床观察  

Clinical observation of iressa on 31 male patients with advanced non-small cell lung cancer

作　　者：胡韡[1] 于力克[1] 

机构地区：[1]南京胸科医院呼吸一科,南京210029

出　　处：《临床肿瘤学杂志》2008年第10期904-905,共2页Chinese Clinical Oncology

摘　　要：目的:观察吉非替尼(Iressa)对男性晚期非小细胞肺癌(NSCLC)患者疗效及毒副反应。方法:31例经病理组织学或细胞学确诊的男性晚期NSCLC口服Iressa250mg/d,直至病灶进展或出现不可耐受的副反应,每月CT扫描,评价疗效,同时记录不良反应。结果:31例入选患者中,30例可评价疗效,无完全缓解(CR),部分缓解(PR)6例,均为肺腺癌,稳定(SD)12例,其中鳞癌1例,12例病情进展(PD),有效率(RR)为20%(6/30),疾病控制率(CR+PR+SD)为60%(18/30),中位肿瘤进展时间5个月,1年生存率40%。最常见的毒副反应为皮疹和腹泻。结论:对于无法耐受化疗或化疗失败的亚洲男性晚期NSCLC患者,尤其是肺腺癌患者,持续口服吉非替尼同样是较理想的方案。Objective：To observe the efficacy of iressa on male patients with advanced non-small cell lung cancer（NSCLC）.Methods：Thirty-one male patients with advanced NSCLC pathologically or cytologically proved was enrolled in this study.Orally iressa 250mg daily were given to these patients until severe toxicity or disease progress occurred,CT scan was performed for response assessment every month.Results：Among 31 patients,30 could be evaluated,no complete response（CR）,6 partial response（PR）were observed,they were all adenocarcinoma,12 stable disease,1 was squama carcinoma.12 progress disease.The overall response rate was 20%（6/30） and disease control rate including both tumor response and stable disease was 60%（18/30）,median time to progress of entire group was 5 months.One year＇ survival rate was 40%.The most common toxicity of iressa was skin toxicity（rash） and diarrhea.Conclusion：Iressa can also be an ideal choice for the male patients with advanced NSCLC who were intolerable or failed prior chemotherapy in asia.

关 键 词：吉非替尼 非小细胞肺癌 男性 

分 类 号：R734.2[医药卫生—肿瘤]